TL;DR
Type I interferons (IFN-I), key players in immune responses, induce the enzyme ACSL1 in macrophages. This induction is crucial for creating a reservoir of saturated phosphatidic acid (PA), which protects these immune cells from damage caused by saturated fatty acids, particularly in conditions like lupus and atherosclerosis.
What Problem Does This Paper Address?
Inflammatory signals, like Type I interferons (IFN-I), are known to increase the expression of long-chain acyl-CoA synthetase 1 (ACSL1) in immune cells, particularly macrophages. While ACSL1 is essential for fatty acid metabolism (like beta-oxidation), the precise reason for its induction by inflammatory mediators in immune cells has been unclear. This study aims to unravel the specific role of IFN-I-induced ACSL1 in macrophages, especially in the context of inflammatory diseases where IFN-I signaling is heightened, such as Systemic Lupus Erythematosus (SLE) and atherosclerosis. The authors hypothesize that this induction might be a protective mechanism against fatty acid-induced cellular damage.
Methods
The researchers employed a multi-pronged approach:
- In vitro studies: They used bone marrow-derived macrophages (BMDMs) from both wild-type and ACSL1-deficient mice. These cells were stimulated with IFN-I and other inflammatory signals.
- In vivo studies: They utilized a mouse model with myeloid cell-specific ACSL1 deficiency and a pristane-induced lupus model, as well as an atherosclerosis model.
- Omics analyses: Comprehensive lipidomics, proteomics, and metabolomics were performed to get a broad picture of cellular changes.
- Functional assays: These included measuring cell death (apoptosis and necrosis), proliferation, efferocytosis (clearance of dead cells), oxygen consumption rate (OCR), and extracellular acidification rate (ECAR).
- Molecular analyses: Real-time PCR and Western blotting were used to assess gene and protein expression.
- Human samples: Peripheral blood mononuclear cells (PBMCs) from individuals with SLE and healthy controls were analyzed for ACSL1 expression.
Datasets
The study utilized:
- Mouse models: Wild-type C57BL/6J mice, myeloid cell-targeted ACSL1-deficient mice (ACSL1M-/-), Ifnar-/- mice, Irf3/7-/- mice, Ldlr-/- mice.
- Human samples: PBMCs from a discovery cohort of 46 SLE patients and 20 healthy controls, and a replication cohort of 19 SLE patients and 16 controls.
- Publicly available data: Expression profiling arrays from a previous study were mined for myeloid cell ACSL1 expression in SLE patients.
Key Insights and Ideas
- ACSL1 as an IFN-I effector: IFN-I directly induces ACSL1 in macrophages via the IFNAR receptor. This is not just a general inflammatory response but a specific pathway.
- ACSL1 and saturated PA: The primary role of IFN-I-induced ACSL1 in macrophages is to increase the accumulation of fully saturated phosphatidic acid (PA) species. This is a novel finding, suggesting a specific lipid remodeling function.
- Protective mechanism: This saturated PA accumulation appears to be a protective mechanism, shielding macrophages from saturated fatty acid-induced apoptosis and secondary necrosis.
- Dual strategy: IFN-I employs a two-pronged approach: inducing ACSL1 to create saturated PA and suppressing lipin 1 (an enzyme that converts PA to DAG), further enhancing saturated PA levels.
- Human relevance: Elevated ACSL1 expression is observed in myeloid cells of individuals with SLE, linking this mechanism to a human autoimmune disease characterized by IFN-I overproduction.
- Specificity of ACSL1's role: ACSL1 is not required for IFN-I's canonical effects on inducing IFN-stimulated genes, suppressing proliferation, or altering macrophage metabolism (OCR/ECAR). Its role is specifically tied to lipid metabolism and cell survival under lipotoxic stress.
Key Results
- IFN-I significantly increased ACSL1 mRNA and protein levels in WT macrophages, but not in ACSL1-deficient ones.
- In WT macrophages, IFN-I treatment led to a significant increase in fully saturated PA species (e.g., 14:0_16:0 PA, 16:0_18:0 PA), an effect absent in ACSL1-deficient macrophages.
- ACSL1-deficient macrophages showed increased apoptosis and secondary necrosis when exposed to saturated fatty acids, especially in the presence of IFN-I.
- In a mouse model of atherosclerosis with IFN overproduction, myeloid cell-specific ACSL1 deficiency led to larger necrotic core areas in lesions.
- ACSL1 deficiency did not affect the expression of typical IFN-stimulated genes (like ISG15, IRF7), cell surface markers (CD80, CD86, MHC II), proliferation, efferocytosis, or core metabolic parameters (OCR, ECAR) in response to IFN-I.
- ACSL1 mRNA levels were significantly elevated in PBMCs from SLE patients compared to controls, and this elevation correlated with IFN scores.
Limitations and Future Work
- Mechanism of PA reservoir function: While the study shows that saturated PA accumulation is important, its precise function as a "reservoir" and how it protects cells remains to be fully elucidated. Further studies are needed to explore this.
- Broader implications for other inflammatory mediators: The study focused on IFN-I. The authors suggest that ACSL1 induction might be a general strategy for other inflammatory mediators as well, which warrants further investigation.
- Role in other diseases: The link to SLE and atherosclerosis is established, but the role of this ACSL1-IFN-I-PA axis in other inflammatory or metabolic diseases could be explored.
- Discrepancies in cell death studies: The authors acknowledge that their findings on cell death differ from some previous studies, suggesting that experimental design, cell type sensitivity, or the balance between cell death and efferocytosis might explain these discrepancies.
- Lysosomal maturation in SLE: The potential link between lipin-1 downregulation, impaired lysosomal maturation, and the pathogenesis of SLE is an interesting avenue for future research.
Summary updated